Switch to:
More From Other Websites
Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog Jul 02 2015
10 Best Biotech Stocks in the NASDAQ Jul 01 2015
EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jul 01 2015
Exelixis Provides Update on Genentech’s Pending New Drug Application for Cobimetinib, an... Jul 01 2015
Biotech Stock Mailbag: Exelixis, Puma Bio Jun 26 2015
5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary Jun 25 2015
Exelixis, Inc. (EXEL) in Focus: Stock Adds 7.5% in Session - Tale of the Tape Jun 22 2015
Watch These 10 Stocks Over The Weekend Jun 20 2015
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer Jun 07 2015
ASCO Reaffirms Why I'm Holding Exelixis Jun 05 2015
Notable option activity in equities Jun 01 2015
6 Key Cancer Winners From ASCO Presentations Jun 01 2015
Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in... May 31 2015
Exelixis Announces Positive Results from Phase 2 Trial of Cabozantinib in Patients with EGFR... May 31 2015
Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the... May 30 2015
Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the... May 30 2015
EXELIXIS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK